Commercializing a novel platform for delivery of antisense oligonucleotide-mediated therapy

将用于反义寡核苷酸介导的治疗的新平台商业化

• 批准号: 462420
• 负责人: Yokota Toshifumi
• 金额: $ 73.56万
• 依托单位: University of Alberta
• 依托单位国家: 加拿大
• 项目类别: Operating Grants
• 财政年份: 2022
• 资助国家: 加拿大
• 起止时间: 2022-03-01 至 2027-03-01
• 项目状态: 未结题
• 来源: https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=462420&lang=en
• 关键词: Antisense Oligonucleotide-Mediated Therapy

To date, approximately 7,000 rare genetic diseases have been identified, which affect 1 in 12 or nearly 3 million Canadians combined. Artificial small DNA-like molecules called antisense oligonucleotides (AOs) are emerging tools for the treatment of genet

到目前为止，已确认约7000种罕见遗传病，影响到每12个加拿大人中就有一个，或者说加起来近300万加拿大人。被称为反义寡核苷酸(Aos)的人工类dna小分子是一种新兴的基因治疗工具。